Champions Oncology Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Champions Oncology Inc (CSBR) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Champions Oncology Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 61M vs 483M combined for tracked competitors (11.2% combined share).
- Trending: Latest-quarter revenue run-rate is holding steady (+0.4% annualized vs trailing 12 months), vs accelerating (+48.8%) for its tracked peer group.
- Growth: Champions Oncology Inc generated 8.8% revenue growth year over year in Q1 2026, vs 123.8% for its tracked competitors combined.
- Profitability: Its -2.8% net margin compares with -18.5% for the peer group.
- Scale: Champions Oncology Inc ranks #115 of 165 companies by market capitalization in the Biotechnology & Pharmaceuticals industry, holding 0.0% of industry market cap.
- Peer revenue share: Champions Oncology Inc accounted for 7.8% of combined revenue among its tracked peer group, down from 14.9% a year earlier.
- Peer differentiation: Revenue per employee of $0.28M compares with $2.42M for the peer group (0.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
CSBR Sales vs. its Competitors, Q1 2026
Champions Oncology Inc reported revenue growth of 8.84 % year on year in Q1 2026, below its competitors' combined revenue growth of 123.80 %.
With a net margin of -2.80 %, Champions Oncology Inc achieved higher profitability than its competitors (-18.51 %).
Champions Oncology Inc generated 7.82 % of the combined sales of its peer group, down from 14.85 % a year earlier.
Champions Oncology Inc vs. its Competitors, Q1 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Champions Oncology Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Champions Oncology Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (10) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (6) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Champions Oncology Inc's competitor groups requires a Commercial License.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 20.7% year over year, combined, vs 8.8% for Champions Oncology Inc. Champions Oncology Inc's share of combined industry revenue moved from 0.04% to 0.03%, a gain of 0.00 percentage points.
Champions Oncology Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Champions Oncology Inc | Yes | Yes | No | No |
| Competitors combined (5) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 62.50 % (5 of 8) | 62.50 % (5 of 8) | 50.00 % (4 of 8) | 12.50 % (1 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CSBR Stock Performance relative to its Competitors
CSBR Stock Performance relative to Similar-Size Competitors
CSBR Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Adaptive Biotechnologies Corporation | 282.9% | Outperformed |
| 2 | Regenxbio Inc | 282.9% | Outperformed |
| 3 | Cellectis S a | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Champions Oncology Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Champions Oncology Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Champions Oncology Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Champions Oncology Inc | 68.51 | 60.66 |
| Adaptive Biotechnologies Corporation | 4,557.47 | 308.08 |
| Regenxbio Inc | 396.03 | 174.48 |
| Cellectis S a | 148.41 | 72.95 |
| Sensei Biotherapeutics Inc | 129.06 | - |
| Vista Energy S a b De C v | - | 2,474.20 |
| SUBTOTAL | 5,299.49 | 3,090.37 |
Sources: Champions Oncology Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Champions Oncology Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Champions Oncology Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Adaptive Biotechnologies Corporation | Mrd Business Segment 92.47 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Champions Oncology Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Champions Oncology Inc | 69 | 283,467 | 181 |
| Adaptive Biotechnologies Corporation | 4,557 | 493,720 | -102,548 |
| Regenxbio Inc | 396 | 470,302 | -529,466 |
| Cellectis S a | 148 | 318,555 | -295,166 |
| Sensei Biotherapeutics Inc | 129 | - | -6,742,345 |
| Vista Energy S a b De C v | - | - | - |
| PEERS TOTAL | 5,231 | 2,417,964 | 156,042 |
Champions Oncology Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 159 companies in Champions Oncology Inc's industry classification, broader than the peer set above. Market cap in millions of $.Champions Oncology Inc ranks #115 of 159 companies by market capitalization in its industry, holding 0.01 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,331, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 226,707 | 26.02 % |
| 2 | Gilead Sciences Inc | 185,928 | 21.34 % |
| 3 | Moderna Inc | 76,517 | 8.78 % |
| 4 | Argenx Se | 63,326 | 7.27 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Exelixis Inc | 1,234 | 5.2% |
| 9 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
| 10 | Halozyme Therapeutics Inc | 1,234 | 5.2% |
| 115 | Champions Oncology Inc | 68 | 0.01 % |
Market cap and industry share for the rest of Champions Oncology Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Champions Oncology Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 110 | Cognition Therapeutics inc | 84 | -26.19 % |
| 111 | Cardiff Oncology Inc | 84 | -40.12 % |
| 112 | Pelthos Therapeutics Inc | 79 | -32.79 % |
| 113 | Imagenebio Inc | 76 | -42.79 % |
| 114 | Kalaris Therapeutics Inc | 1,234 | 12.3% |
| 115 | Champions Oncology Inc | 68 | -23.16 % |
| 116 | Leonabio Inc | 1,234 | 12.3% |
| 117 | Scilex Holding Company | 1,234 | 12.3% |
| 118 | Mink Therapeutics Inc | 1,234 | 12.3% |
| 119 | Aligos Therapeutics Inc | 1,234 | 12.3% |
| 120 | Inmune Bio Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Champions Oncology Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Champions Oncology Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Biotechnology & Pharmaceuticals industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (93 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 49.82 % | 68.46 % (avg) | -18.6 pp |
| Operating Margin | -1.68 % | industry median | +203.3 pp |
| EBITDA Margin | 3.03 % | -0.94 % (avg) | +4.0 pp |
| Capital Intensity (Capex / Revenue) | 0.94 % | 6.74 % (avg) | -5.8 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Champions Oncology Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (93 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.7x | - |
| EV / EBITDA | 41.5x | 21.3x | +20.2x |
| P/B | 20.2x | 5.1x | +15.1x |
| Return on Equity | 0.94 % | industry aggregate | 4.37 % |
| Return on Invested Capital | -5.07 % | -6.17 % (avg) | 1.10 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Champions Oncology Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 31.03 % | 27.49 % | 28.11 % | 26.15 % | 19.30 % | -8.29 % | 19.03 % | -1.10 % |
| Operating Margin | -16.54 % | -0.87 % | -0.02 % | -2.85 % | 1.05 % | -19.51 % | 10.73 % | -4.53 % |
| Return on Invested Capital | -304.23 % | -6.44 % | -0.08 % | -6.14 % | 1.96 % | -98.92 % | 149.87 % | -9.88 % |
| P/E | - | - | - | - | 298.4x | - | 15.8x | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Champions Oncology Inc's Strategic Group Map
Every company in Champions Oncology Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Champions Oncology Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Champions Oncology Inc's BCG Growth-Share Matrix
Relative market share (vs Champions Oncology Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Champions Oncology Inc falls in the Question Mark quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 10.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Champions Oncology Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,331 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.94 % vs industry average 6.74 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Champions Oncology Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Champions Oncology Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Champions Oncology Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Champions Oncology Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Champions Oncology Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 203.3 points above the industry median.
Weaknesses
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
- Industry revenue growing at a healthy 10.0% median pace.
- A meaningful share of tracked competitors (40.00 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Champions Oncology Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Champions Oncology Inc | 0.33 | 0.97 | - |
| Adaptive Biotechnologies Corporation | 1.07 | 3.72 | 0.49 |
| Regenxbio Inc | 0.54 | 2.61 | - |
| Cellectis S a | 0.42 | 1.76 | - |
| Sensei Biotherapeutics Inc | 6.11 | 13.56 | - |
| Vista Energy S a b De C v | 0.19 | 0.32 | 1.12 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Champions Oncology Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Champions Oncology Inc | Q2 2026 | +8.8 % | - |
| Adaptive Biotechnologies Corporation | Q2 2026 | +21.5 % | - |
| Regenxbio Inc | Q2 2026 | +405.7 % | - |
| Cellectis S a | Q4 2025 | +75.8 % | - |
| Sensei Biotherapeutics Inc | Q2 2026 | - | - |
| Vista Energy S a b De C v | Q4 2025 | +50.2 % | +50.6 % |
| PEERS TOTAL | +53.7 % | +82.3 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Champions Oncology Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Champions Oncology Inc | Q2 2026 | -5.8 % | +19.6 % |
| Adaptive Biotechnologies Corporation | Q2 2026 | +12.0 % | +80.8 % |
| Regenxbio Inc | Q2 2026 | - | +94.4 % |
| Cellectis S a | Q4 2025 | - | -8.6 % |
| Sensei Biotherapeutics Inc | Q2 2026 | - | - |
| Vista Energy S a b De C v | Q4 2025 | +56.5 % | +38.3 % |
Champions Oncology Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Champions Oncology Inc | 0.13% | 0.18% | 0.94% |
| Adaptive Biotechnologies Corporation | - | - | - |
| Regenxbio Inc | - | - | - |
| Cellectis S a | - | - | - |
| Sensei Biotherapeutics Inc | - | - | - |
| Vista Energy S a b De C v | 10.11% | 16.39% | 28.63% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Champions Oncology Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Champions Oncology Inc | - | 1.13 |
| Adaptive Biotechnologies Corporation | - | 14.79 |
| Regenxbio Inc | - | 2.27 |
| Cellectis S a | - | 2.03 |
| Sensei Biotherapeutics Inc | - | - |
| Vista Energy S a b De C v | - | - |
| PEERS AVERAGE | 27.10 | 1.71 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.